Ribomic

Ribomic Rule of 40

The Rule of 40 of Ribomic (4591.T) as of Oct 30, 2026 is -40,195.35 %. In the previous year, Rule of 40 was -2,725.86 % — a change of 1,374.59% (lower).

Rule of 40

-40,195.35 %

YoY

1,374.59%

Last updated:

Rule of 40 of Ribomic is 2026 -40,195.35 % . Rule of 40 of Ribomic was 2025 -2,725.86 % . It decreases by 1,374.59% lower compared to the previous year.

The Ribomic Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2017
-861.17 JPY
Jan 1, 2018
-1,421.27 JPY
Jan 1, 2019
-11,770.02 JPY
Jan 1, 2020
673.59 JPY
Jan 1, 2021
-1,372.22 JPY
Jan 1, 2022
-2,172.61 JPY
Jan 1, 2023
-2,725.86 JPY
Jan 1, 2026
-40,195.35 JPY
The Ribomic Rule of 40 history
YEARRule of 40YoY
-40,195.35 %+1,374.59%
-2,725.86 %+25.46%
-2,172.61 %+58.33%
-1,372.22 %-303.72%
673.59 %-105.72%
-11,770.02 %+728.14%
-1,421.27 %+65.04%
-861.17 %+68.43%
-511.30 %-333.87%
218.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ribomic Stock analysis

What does Ribomic do? Ribomic, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for therapeutic applications. Headquartered in Minato-Ku, Tokyo-To, the company utilizes its workforce of 25 full-time employees to drive its drug discovery operations, which are structured into self discovery and co-discovery divisions. This operational framework allows the firm to focus on advancing RNA aptamer technologies for medical use. The Self Drug Discovery division develops aptamers and licenses these results to pharmaceutical companies, generating revenue through intellectual property transfers. Meanwhile, the Co-Discovery division collaborates with alliance pharmaceutical companies researching aptamer pharmaceuticals. This segment earns research expenses paid by the alliance partners for the shared portion of the co-discovery business, creating a dual revenue stream based on licensing and collaborative research fees. Ribomic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ribomic stock

Rule of 40 of Ribomic is -40,195.35 % in 2026.

On Eulerpool you can find the complete historical development of Rule of 40 Ribomic since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Ribomic

All Key Metrics — Ribomic